...
首页> 外文期刊>Bratislava Medical Journal >Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension
【24h】

Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension

机译:西地那非与波生坦治疗单芥子油碱诱发的肺动脉高压的临床和组织病理学关系

获取原文
           

摘要

BACKGROUND: Pulmonary arterial hypertension (PAH) is a challenging disorder characterized by increasing pulmonary artery pressure, which is hard to treat. OBJECTIVE: This study was aimed to investigate the effects of bosentan, sildenafil and their combination. METHODS: Saline or MCT were applied to Wistar rats. By the development of PAH (4th week), MCT-given rats were treated orally with bosentan, sildenafil and combination of sildenafil and bosentan or placebo. ECHO examinations were performed. Tissues obtained from all of the rats were evaluated under an electron microscope. RESULTS: Left ventricular end diastolic diameter significantly increased in sildenafil and combined groups. Sildenafil group revealed a significant decrease in RV pressure and wall thickness. Examination of lung revealed a significant amount of connective tissue formation and increase in inflammatory cells in all the groups except controls in the interalveolar septum. Examination of PA revealed an increase in connective tissue volume, hypertrophic changes and expansions in granular endoplasmic reticulum cisternaes in smooth muscle cells in active groups rather than in the controls. Unlike the controls, the examination of the RV revealed an enlargement of the sarcoplasmic reticulum cisternaes in some cells, due to the calcium increase.CONCLUSION: Sildenafil and the combined therapy demonstrated to have more impact on pressure and the RV parameters in rats, with lower inflammatory findings in lung tissue (Fig. 6, Ref. 31). Keywords: bosentan, pulmonary hypertension, sildenafil Published online: 18-Oct-2017 Year: 2017, Volume: 118, Issue: 9 Page From: 544, Page To: 551 doi:10.4149/BLL_2017_104 download file ? AEPress s.r.o Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.
机译:背景:肺动脉高压(PAH)是一种具有挑战性的疾病,其特征是肺动脉压升高,难以治疗。目的:本研究旨在研究波生坦,西地那非及其组合的作用。方法:将盐或MCT应用于Wistar大鼠。通过PAH的发展(第4周),给予MCT的大鼠口服波生坦,西地那非以及西地那非和波生坦或安慰剂的组合进行口服治疗。进行了ECHO检查。在电子显微镜下评价从所有大鼠获得的组织。结果:西地那非和联合治疗组左心室舒张末期直径明显增加。西地那非组显示RV压力和壁厚显着降低。肺部检查显示,除肺泡间隔中的对照组外,所有组中结缔组织的形成均明显,炎症细胞增多。对PA的检查显示,在活动组而不是对照组中,平滑肌细胞的结缔组织体积增加,肥大性改变和颗粒状内质网池的扩张。与对照组不同,右室检查发现由于钙的增加,某些细胞的肌浆网池增大。结论:西地那非和联合疗法对大鼠的压力和右室参数有更大的影响,较低肺组织中的炎症结果(图6,参考文献31)。关键字:波生坦,肺动脉高压,西地那非在线发布时间:2017年10月18日年份:2017,数量:118,版本:9页面来源:544,页面收件人:551 doi:10.4149 / BLL_2017_104下载文件? AEPress s.r.o版权声明:有关复制,存档或以其他方式使用ELiS中的文档的任何许可,请联系AEP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号